Efficacy and safety of tocilizumab monotherapy in patients with microscopic polyangiitis

Efficacy and safety of tocilizumab monotherapy in patients with microscopic polyangiitis - Tocilizumab mono-therapy for microscopic polyangiitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011242

Enrollment

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microscopic polyangiitis

Interventions

tocilizumab monotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who fulfilled the 2007 Watts algorithm. 1) Watts R et al. Development and validation of a consensus methodology for the classification of theANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007 Feb; 66(2): 222-7.

Exclusion criteria

Exclusion criteria: 1) patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use 2) patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor

Design outcomes

Primary

Measure	Time frame
Improvement of major clinical signs and symptoms at week 24. (MPO-ANCA or PR3-ANCA, serum CRP and ESR, BVAS2003, VDI)	—

Secondary

Measure	Time frame
Improvement of major clinical signs and symptoms at week 52 Exacerbation of major clinical signs and symptoms at week 104	—

Countries

Japan

Contacts

Public ContactRyota Sakai

Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology

r_sakai@saitama-med.ac.jp0492283574

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026